Terminology {#sec2-1}
===========

Diverticulosis: the presence of diverticula Diverticular disease: any symptomatic condition involving diverticula

Diverticulitis: diverticular macro inflammation with local pain symptoms

Complicated diverticulitis: abscesses, fistulae, obstructions or perforations

Symptomatic uncomplicated diverticular disease:

diverticula with persistent localised pain and diarrhoea/constipation, without macroscopic inflammation.

Introduction {#sec1-2}
============

Diagnosing the cause of abdominal pain can be challenging ([@ref1]), especially due to the large number of conditions presenting with this symptom ([@ref2]). Clinicians should be vigilant to the possibility of colorectal cancer in patients with this clinical scenario, due to its increasing incidence even among younger patients ([@ref3], [@ref4]). Abdominal pain can result from functional- or structural gastrointestinal (GI) disorders. Functional GI disorders include idiopathic bowel disorders thought to involve visceral hypersensitivity, visceral nociceptors and/or impaired gastrointestinal motility: Irritable bowel syndrome is the major entity in this group ([@ref5]). In contrast, structural GI disorders have an established physical cause such as an infection, neoplastic disease, autoimmune reaction or inflammation; they include various forms of colitis (e.g., infectious or ulcerative colitis, Crohn's disease) and diverticular diseases.

Diverticular disease (DD) is prevalent in western and industrialized societies, and appears to be associated with the low fibre content in the diet ([@ref6], [@ref7]). DD accounts for substantial part of burden of digestive diseases ([@ref8]-[@ref11]).

Diverticula are outpouchings of intestinal colonic mucosal and submucosal layers that protrude through weak points in the colon wall, typically at the points where the vasa rectae traverse. The incidence of this condition, known as diverticulosis, is high, increases with age, and in the great majority of cases remains asymptomatic ([@ref12]). However, approximately 20% of patients will develop symptoms and complications ([@ref13]). The term *diverticular disease* (DD) refers to any condition in which the presence of diverticula is associated with symptoms. Infection/macroscopic inflammation associated with a diverticulum occurs in approximately 15% of symptomatic patients and may progress to extra-colonic infection/inflammation (diverticulitis). Diverticulitis is usually associated with abdominal pain, fever, tachycardia, and elevated markers for inflammation. Diverticulitis can lead to the formation of abscesses, fistulae, obstructions, perforations, or peritonitis, at which point it is known as complicated diverticulitis ([@ref12]). However, \< 50% of patiens with acute diverticulitis, also those complicated with abscesses at CT scan, have the classical clinical triad of abdominal pain, fever and leucocytosis ([@ref14]).

![Classification of diverticular disease and frequency of the various forms](ACTA-88-25-g001){#F1}

Patients with diverticulosis who develop a constellation of persistent abdominal symptoms that include pain and changes in bowel habits that are not, however, associated with macroscopic inflammation or elevated systemic markers of inflammation, may have a condition known as symptomatic uncomplicated diverticular disease (SUDD). The diagnosis of symptoms of SUDD is complicated by the fact that several of its symptoms are common to other conditions that respond to different therapeutic approaches. Therefore, correct diagnosis is critical to the management of SUDD ([@ref15]).

SUDD {#sec1-3}
====

SUDD is defined as the concomitant presence of diverticula and symptoms of abdominal pain and bloating, bowel habit changes that include diarrhoea and constipation or a mixed bowel habit, in the absence of macroscopic inflammation ([@ref16], [@ref17]). The severity and frequency of symptoms may have an impact on daily activities and severely affect quality of life 18); which can be assessed with the DD-specific DV-QoL survey ([@ref19]).

Whereas the exact aetiology is not certain, a number of aspects of this condition have been investigated. Horgan et al. reported on a series of patients undergoing surgery for SUDD (n = 930), in which three-quarter of biopsies from patient who underwent resections showed signs of low-grade peridiverticular inflammation ([@ref20]). It is suggested that chronic low-grade inflammation may provoke visceral hypersensitivity and changes in colonic motility. Patients with SUDD have a heightened sensitivity of isobaric distension (visceral hypersensitivity) compared to asymptomatic patients ([@ref21]). Humes et al. assessed visceral sensitivity in patients with diverticular disease, reporting higher median mRNA levels of the neurokinin 1 receptor and TNF alpha in a group of 12 patients with symptomatic diverticular disease, compared to a group of 13 asymptomatic patients. There was a significant correlation between barostat pain scores and neurokinin 1 receptor expression ([@ref22]). Simpson et al., sought to explain the visceral hypersensitivity observed in patients with SUDD by assessing expression of neuropeptides in peridiverticular biopsies from 17 symptomatic and 15 asymptomatic patients ([@ref23]). Although histology was normal in both groups, there was significantly higher expression of the neuropeptides substance P, neuropeptide K, pituitary adenylate cyclase activating polypeptide, vasoactive intestinal polypeptide and galanin in the symptomatic group. Changes in neuromuscular function may influence colonic motility, causing changes in bowel habits, and may also influence perception of abdominal pain ([@ref24]). Bassotti et al. reported that patients with SUDD have abnormal motor activity and peristaltic action in the colon segments with diverticulosis, including a longer duration of rhythmic, low frequency contractile activity ([@ref25]).

Another putative mechanism in SUDD is the effect on gut microbiota leading to chronic inflammation ([@ref26]). The microbiota of patients with DD have reduced levels of bacterial with anti-inflammatory properties (e.g., Clostridium clusters IV and IX, Fusobacterium, and the Lactobacillaceae); these changes in microbiota are associated with mucosal immune activation ([@ref26]).

Such modifications in intestinal microbiota could result from faecal stasis due to the colonic dysmotility. The overgrowth of intestinal bacteria and chronic dysbiosis could promote inflammation thought the production of abnormal bacterial metabolites. A role for dysbiosis is also suggested by the efficacy of cyclic antibiotic treatment in controlling symptoms ([@ref27]-[@ref31]).

Diagnosing SUDD {#sec1-4}
===============

Diagnosing this condition is complicated by the fact that the symptoms may be difficult to distinguish from those of functional GI disorders such as irritable bowel syndrome (IBS) ([@ref17], [@ref32]) thus several key differences should be used to differentiate between these conditions.

First, the pain associated with SUDD is normally located in the iliac fossa ([Figure 2](#F2){ref-type="fig"}), is more sustained, likely long-lasting or associated with history of pain lasting more than 24 hrs, and is not relieved by bowel movement, as is often the case with IBS ([@ref17], [@ref33]) ([Table 1](#T1){ref-type="table"}).

![Most frequent location of abdominal pain associated with SUDD](ACTA-88-25-g002){#F2}

###### 

Important pain characteristics differentiating SUDD from IBS. (modified from 17)

  Pain characteristics                      SUDD   IBS
  ----------------------------------------- ------ -----
  Diffuse/generalized                       no     yes
  Localised in left iliac fossa             yes    no
  Relieved by passing stool or flatulence   no     yes
  Wakes the patient at night                yes    no

The prevalence of SUDD increases with age ([@ref11]), so that patients under the age of 40 years are less likely to have diverticula. Moreover, SUDD may follow a bout of acute of diverticulitis ([@ref34]).

Imaging {#sec1-5}
=======

Next, is useful to establish whether the patient has diverticulosis, especially if the patient is relatively young. The lack of diverticula would exclude SUDD. Gold standard methods include Computed Tomographic Colonography (CTC) or Colonoscopy ([@ref35]). Although colonoscopy is the most widely used imaging technique for assessing the colon, its accuracy in detecting colonic diverticula, in particular those located in the sigmoid colon, is not superior to that of barium enema and CT colonography ([@ref35]), so that a definite gold standard does not exist. The choice between these methods is therefore based on patient age, risk factors for polyps or cancer, clinical status, patient preference and local availability of the techniques ([@ref16]). However, it is not practical to perform or repeat these examinations on all patients presenting with abdominal symptoms. Instead, we suggest that reference be made, where possible, to recent archival imagine data. When this is not available, recourse to ultrasonography is a useful alternative ([@ref36]). Advantages of ultrasonography include that it is less invasive, has a lower cost and may be more readily available and repeteable than conventional colonoscopy and colonography. It also avoids unnecessary exposure to ionising radiation, which is increasing important as the age of incidence for diverticular disease is decreasing ([@ref37]) and real time examination allows to directly assess the exct site of pain of patients correlating this with the presence of underlying diverticula. So far, the accuracy of US in detecting left-sided diverticulosis has been assessed in only one prospective study that enrolled 60 patients and used colonoscopy as reference standard, showing a sensitivity of 85% with only 2 false positive results ([@ref38]).

Biochemical markers {#sec1-6}
===================

CRP is a general marker of inflammation that is useful for distinguishing patients with diverticulitis, or other overtly inflammatory condition. It is not specific for diverticular disease. Faecal calprotectin is a surrogate marker for intestinal inflammation. Calprotectin is a protein produced by neutrophils. Elevated levels in the faeces are indicative of inflammation of the intestinal mucosa, including inflammation caused by IBD or bacterial infections. It is a relatively nonspecific test that can be positive not only for inflammatory bowel diseases, but also coeliac disease, infectious colitis, necrotizing enterocolitis, intestinal cystic fibrosis and colorectal cancer. Whereas, non-inflammatory conditions like FAPS and IBS are negative. Reference ranges have been established, with cut-offs indicative of various conditions. The test can be used to measure disease activity status and response to therapy in IBD ([@ref39]). It can inform differential diagnosis, as levels are only mildly elevated in patients with SUDD, but not in patients with IBS ([@ref40]). Also in SUDD, levels correlate with symptom severity ([@ref41]).

Treatment with Rifaximin {#sec1-7}
========================

Introduction of Rifaximin {#sec2-2}
-------------------------

Background on pharmacology and mechanism {#sec2-3}
----------------------------------------

Rifaximin is a hydrophobic rifampicin derivative with negligible GI absorption. This property avoids systemic side effects and at the same time provides high faecal antibiotic concentrations ([@ref42]). It inhibits gene transcription in both gram positive and gram negative bacterial by binding to the p-subunit of bacterial DNA-dependent RNA polymerase. Cyclic administration of rifaximin combined with soluble fibre supplementation, is useful for treating SUDD. Cyclic treatment with rifaximin consists of administering 400 mg twice daily for 7 days per month for at least 12 months which alleviates symptoms, reduces the risk of recurrence or complications, and improves quality of life. ([@ref27]-[@ref31], [@ref43])

SUDD associated with dysbiosis and reduced level of beneficial bacteria ([@ref26]). Rifaximin has a eubiotic effect on the intestinal microbiota ([@ref44]) that may be accomplished through modulation of both the composition of gut microbiota and bacterial metabolism ([@ref45]). Ponziani et al. conducted a molecular survey of intestinal bacteria before and after 10 days of rifaximin administration in 20 patients with a variety of conditions. The main finding was the increase in beneficial Lactobacilli ([@ref45]). Meanwhile, in a study of 15 patients with IBS not accompanied by constipation, rifaximin increased the presence of beneficial Faecalibacterium prausnitzii after 2 weeks of treatment ([@ref46]). To date, the effect of rifaximin on the gut microbiota has not been assessed in large studies.

Another potential mechanism is through anti-inflammatory effects in the gut mucosa ([@ref47]). Rifaximin treatment is associated with a reduction in innate immune effector cells in the colonic mucosa ([Figure 3](#F3){ref-type="fig"})

![Rifaximin reduced mucosal CD103+ gamma-delta T cells, supporting the anti-inflammatory activity of rifaximin (figure from 48 modified)](ACTA-88-25-g004){#F3}

Moreover, bacteria are known to induce inflammation by interacting with toll-like receptors that influence innate immunity and T-cell recruitment. Cianci et al. randomly assigned 40 consecutive asymptomatic patients with uncomplicated DD to receive either rifaximin or placebo. Expression of Toll-like receptors 2 and 4, and intestinal homing of innate immune cells were assessed in colonic mucosal biopsies at baseline and after 2 months of treatment. Rifaximin treatment normalised the distribution or toll-like receptor expression that is altered in patients with diverticular disease ([@ref47]).

Putative additional mechanisms that may explain the observed clinical activity of rifaximin include decreasing bacterial adherence to epithelial cells, inhibiting their translocation across the GI epithelium, as well as activating the pregnane X receptor and thereby reducing levels of the proinflammatory transcription factor nuclear factor κB.

Thus, rifaximin may work directly on gut bacteria and indirectly through host factors that may modify bacterial interactions with the intestinal mucosa and reduce inflammation ([@ref44]).

Efficacy {#sec2-4}
--------

Five randomized controlled studies have compared rifaximin with placebo or fibre supplementation ([@ref27]-[@ref31]). A meta-analysis of these trials (n = 1660) revealed a 29.0% improvement in complete symptom resolution with rifaximin (Rifaximin vs. control; 95% CI 24.5-33.6; P\<0.0001) ([@ref49]), corresponding to a number needed to treat of 3 patients, in order to see a benefit in terms of complete resolution of symptoms.

The largest trial was a prospective 12-month study in 968 patients with SUDD randomized to receive fibre supplementation (glucomannan 4 g/day) alone (n=346) or glucomannan plus daily rifaximin 400 mg/day for 7 days every month (n=558) ([@ref29]). The primary outcome was symptomatic relief at 12 months, evaluated by symptom frequency and a global symptom score comprising upper and lower abdominal pain, bloating, tenesmus, diarrhoea, and abdominal tenderness. The secondary outcome was the incidence of complications, defined as development of diverticulitis or rectal bleeding. Adding rifaximin resulted in fewer individual symptoms and a lower global symptom score ([Figure 4](#F4){ref-type="fig"}). After 12 months, 56.5% of patients receiving glucomannan plus rifaximin were asymptomatic, compared to 29.2% with glucomannan alone (P\<0.001). Incidence of AD or rectal bleeding was lower in the group receiving rifaximin (1.34% with rifaximin plus glucomannan vs. 3.22% with glucomannan alone (P\<0.05).

![Global symptomatic score is the sum of scores for six clinical variables: upper abdominal pain/discomfort, lower abdominal pain/discomfort, bloating, tenesmus, diarrhea, and abdominal tenderness, graded from 0 (no symptoms) to 3 (severe, incapacitating) (image adapted from 29)](ACTA-88-25-g005){#F4}

                                                         Controls (n = 88)   Treated (n = 77)
  ------------------------------------------------------ ------------------- ------------------
  Patients with events[\*](#t2f1){ref-type="table-fn"}   6                   8
  Articular pain/discomfort                              3                   2
  Increased hypercholesterolemia                         2                   0
  Increased weight                                       1                   1
  Increased uricaemia                                    1                   0
  Increased glycemia                                     1                   0
  Cold/pulmonary phlegm                                  1                   1
  Itching                                                0                   2
  Anxiety                                                0                   2
  Diarrhoea at each administration                       0                   1
  Increased triglycerides                                0                   1
  Epididymitis                                           0                   1

Patients could report more than one event. (Adapted from 50)

Tolerability of cyclic administration in patients with SUDD {#sec2-5}
-----------------------------------------------------------

Several long term studies have provided evidence that rifaximin is well tolerated, with adverse events with cyclic administration not significantly different from those in the control groups ([@ref49]-[@ref51]). Lanas et al. have reported potentially treatment-related adverse events during a 48-week study of 165 patients with recent diverticulitis randomized to receive 3.5 g of fibre supplementation, with/without one week per month of rifaximin 400 mg twice daily ([@ref50]).

Stallinger et al. conducted a non-interventional study of 1,054 adult patients with SUDD treated as outpatients with cyclic administration of rifaximin ([@ref51]). Clinical visits were held at baseline and monthly thereafter for three months. During the study, 24 adverse events were reported by 20 patients; six of these were related to the use of rifaximin, corresponding to an adverse event rate of 0.6%. Five events were GI adverse events (flatulence/1 patient; abdominal pain/1 patient; nausea/3 patients) and 1 was a skin rash. One reason for the low frequency of adverse events is that the alpha polymorphic form of rifaximin has negligible gut absorption and systemic availability ([@ref52]).

Conclusions {#sec1-8}
===========

SUDD is a multifactorial condition for which the correct diagnosis, although often difficult to obtain, provides the highest probability of successful management. To achieve this, we suggest combining a careful assessment of the pain characteristics, with cross-sectional imaging to ascertain diverticulosis status and laboratory tests to exclude overt inflammation. The presence of a moderate level of faecal calprotectin may help to distinguish SUDD from non-inflammatory conditions such as IBS, which are completely negative, and inflammatory conditions such as Crohn's disease, ulcerative colitis, and diverticulitis, which are clearly positive.

Once correctly diagnosed, it is important to address the condition with effective therapy. Fibre supplementation plus cyclic treatment with rifaximin is well-tolerated in patients with SUDD and effective at controlling symptoms. Once symptom control has been achieved, it is important to consolidate and maintain these advances through cyclic administration of daily rifaximin for one week each month.

On the basis of this we can conclude that the best approach for managing SUDD involves three basic steps: - **Divert**, that means approaching patients with abdominal pain in a different way, to make the correct diagnosis of SUDD; - **Tackle** the condition by providing the appropriate treatment, able to improve symptoms by acting on causes, and - **Maintain**, engaging patients to let them understand the importance of cyclic treatment, to insure long-term recovery.
